Revelation Biosciences Q1 net loss $2.1M; cash only to June 2025

REVELATION BIOSCIENCES, INC.

2025-Q1 EPS reported -$2.11

Cash and equivalents $3.7M at March 31, 2025, down from $6.5M at Dec 31, 2024.
Net loss $2.1M ($2.11 per share) vs $2.7M ($39.37 per share) in Q1 2024.
Operating cash burn $2.8M in Q1 2025, same as Q1 2024.
Management says current cash sufficient only through June 2025.
New indication for Gemini in severe burns; topline PRIME Phase 1b data expected summer 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.